Latest News

Phase 2 Trial of ZL-1102 for Psoriasis Begins
Phase 2 Trial of ZL-1102 for Psoriasis Begins

May 29th 2024

The treatment is the first IL-17 targeting topical therapy being developed for less severe cases of psoriasis.

Low Stress Resilience in Men Linked to Higher Risk of Psoriasis and Psoriatic Arthritis
Low Stress Resilience in Men Linked to Higher Risk of Psoriasis and Psoriatic Arthritis

May 29th 2024

Efficacy of Risankizumab For Severe Psoriasis
Efficacy of Risankizumab For Severe Psoriasis

May 28th 2024

Innovent's Picankibart (IBI112) Achieves Phase 3 Clinical Success in Moderate to Severe Plaque Psoriasis
Innovent's Picankibart (IBI112) Achieves Phase 3 Clinical Success in Moderate to Severe Plaque Psoriasis

May 28th 2024

IL-17 Pathway Linked to HIF-1-alpha Activation in Psoriasis
IL-17 Pathway Linked to HIF-1-alpha Activation in Psoriasis

May 22nd 2024

Latest CME Events & Activities

More News

© 2024 MJH Life Sciences

All rights reserved.